Alcobra Ltd (NASDAQ:ADHD) has been downgraded to Hold in a statement by Stifel Nicolaus earlier today.
- Updated: October 7, 2016
Stifel Nicolaus has downgraded Alcobra Ltd (NASDAQ:ADHD) to Hold in a statement released on Friday October 07, 2016.
Just yesterday Alcobra Ltd (NASDAQ:ADHD) traded -0.38% lower at $2.55. Alcobra Ltd’s 50-day moving average is $4.41 and its 200-day moving average is $4.46. The last closing price is down -41.94% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Trading volume was up over the average, with 377,083 shares of ADHD changing hands over the typical 289,497
Recent Performance Chart
Alcobra Ltd has with a 52 week low of $1.95 and a 52 week high of $8.78 and has a market capitalization of $0.
In addition to Stifel Nicolaus reporting its stock price target, a total of 7 brokerages have issued a research note on the company. The average stock price target is $12.71 with 3 firms rating the stock a strong buy, 3 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally zero analysts rating the company a sell.
More About Alcobra Ltd (NASDAQ:ADHD)
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.